PL2576776T3 - Modyfikowane beta-laktamazy oraz powiązane z nimi sposoby i zastosowania - Google Patents

Modyfikowane beta-laktamazy oraz powiązane z nimi sposoby i zastosowania

Info

Publication number
PL2576776T3
PL2576776T3 PL11786185T PL11786185T PL2576776T3 PL 2576776 T3 PL2576776 T3 PL 2576776T3 PL 11786185 T PL11786185 T PL 11786185T PL 11786185 T PL11786185 T PL 11786185T PL 2576776 T3 PL2576776 T3 PL 2576776T3
Authority
PL
Poland
Prior art keywords
lactamases
methods
modified beta
uses related
beta
Prior art date
Application number
PL11786185T
Other languages
English (en)
Inventor
Pertti Koski
Ulla Airaksinen
Katja VÄLIMÄKI
Original Assignee
Synthetic Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Biologics, Inc. filed Critical Synthetic Biologics, Inc.
Publication of PL2576776T3 publication Critical patent/PL2576776T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006Beta-lactamase (3.5.2.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
PL11786185T 2010-05-24 2011-05-17 Modyfikowane beta-laktamazy oraz powiązane z nimi sposoby i zastosowania PL2576776T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20105572A FI20105572A0 (fi) 2010-05-24 2010-05-24 Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt

Publications (1)

Publication Number Publication Date
PL2576776T3 true PL2576776T3 (pl) 2017-01-31

Family

ID=42234353

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11786185T PL2576776T3 (pl) 2010-05-24 2011-05-17 Modyfikowane beta-laktamazy oraz powiązane z nimi sposoby i zastosowania

Country Status (16)

Country Link
US (11) US9034602B2 (pl)
EP (1) EP2576776B1 (pl)
JP (1) JP5827681B2 (pl)
KR (1) KR101708703B1 (pl)
CN (1) CN103038341B (pl)
AU (1) AU2011257092C1 (pl)
BR (1) BR112012030029B1 (pl)
CA (1) CA2800671C (pl)
DK (1) DK2576776T3 (pl)
ES (1) ES2588279T3 (pl)
FI (1) FI20105572A0 (pl)
HU (1) HUE030689T2 (pl)
PL (1) PL2576776T3 (pl)
RU (1) RU2570551C2 (pl)
WO (1) WO2011148041A1 (pl)
ZA (1) ZA201208948B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
CA2942971C (en) * 2014-04-17 2023-03-14 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
EP3186379B1 (en) 2014-08-28 2020-04-08 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
CA2962959C (en) 2014-10-08 2023-04-04 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
CN107530406B (zh) 2015-02-23 2021-10-22 合成生物制品有限公司 用于保护肠微生物群系的与抗生素一起使用的碳青霉烯酶
EP3265119B1 (en) 2015-03-06 2023-10-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
BR112018016889A2 (pt) * 2016-02-23 2019-02-12 Da Volterra variantes de beta-lactamase
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2018005606A1 (en) * 2016-06-28 2018-01-04 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
WO2018085267A1 (en) * 2016-11-01 2018-05-11 Synthetic Biologics, Inc. Methods and compositions for attenuating antibiotic resistance
CN110157699B (zh) * 2018-02-12 2021-07-23 中国科学院微生物研究所 β-内酰胺酶及其编码基因以及它们的应用
WO2020030593A1 (en) 2018-08-05 2020-02-13 Da Volterra Compositions for the treatment of graft versus host disease
EP3829637A1 (en) 2018-08-05 2021-06-09 Da Volterra Method for improving anticancer agent efficacy
CN110777178A (zh) * 2019-12-02 2020-02-11 河北慧林生物科技有限公司 固定化羧基酯水解酶在氯唑西林、双氯西林、氟氯西林及苯唑西林侧链合成中的应用
CN114075560A (zh) * 2020-08-18 2022-02-22 杭州俊丰生物工程有限公司 一种β-内酰胺酶的稳定组合物
EP4148136A1 (en) 2021-09-08 2023-03-15 Da Volterra An engineered yeast cell for the delivery of antibiotic-inactivating enzymes

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL89987C (pl) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
CN1190434A (zh) 1995-07-07 1998-08-12 诺沃挪第克公司 用不能形成芽孢的芽孢杆菌生产蛋白质的方法
CN100439492C (zh) 2001-05-29 2008-12-03 花王株式会社 宿主微生物
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
US7323303B2 (en) * 2003-03-31 2008-01-29 Hong Kong Polytechnic University Modified β-lactamases and uses thereof
EP1564286A1 (en) 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
IL163821A0 (en) * 2004-08-31 2005-12-18 Ravgalai Ltd Rapax Consortium Software for management of legal motions Methods and kits for the detection of biotoxic andantibiotic residues
EP1883396B1 (en) 2005-05-18 2013-07-03 DA Volterra Colonic delivery of adsorbents
FI119190B (fi) * 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
FI119678B (fi) * 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt

Also Published As

Publication number Publication date
HUE030689T2 (en) 2017-05-29
US20190169590A1 (en) 2019-06-06
DK2576776T3 (en) 2016-10-03
EP2576776A4 (en) 2014-01-22
US20150056178A1 (en) 2015-02-26
HK1183905A1 (zh) 2014-01-10
US20150209418A1 (en) 2015-07-30
JP5827681B2 (ja) 2015-12-02
CN103038341B (zh) 2016-04-20
AU2011257092B2 (en) 2013-12-19
US9301995B2 (en) 2016-04-05
US20230332128A1 (en) 2023-10-19
RU2012155420A (ru) 2014-06-27
US9301996B2 (en) 2016-04-05
US9765320B2 (en) 2017-09-19
US11214787B2 (en) 2022-01-04
FI20105572A0 (fi) 2010-05-24
CA2800671C (en) 2018-09-18
KR101708703B1 (ko) 2017-02-21
AU2011257092A1 (en) 2013-01-10
US20140127785A1 (en) 2014-05-08
US9587234B2 (en) 2017-03-07
US20130216622A1 (en) 2013-08-22
US20160168557A1 (en) 2016-06-16
US20220090044A1 (en) 2022-03-24
RU2570551C2 (ru) 2015-12-10
US9034602B2 (en) 2015-05-19
EP2576776A1 (en) 2013-04-10
EP2576776B1 (en) 2016-07-13
BR112012030029B1 (pt) 2021-08-17
KR20130133648A (ko) 2013-12-09
BR112012030029A2 (pt) 2017-05-02
US20170327812A1 (en) 2017-11-16
US10253306B2 (en) 2019-04-09
US8894994B2 (en) 2014-11-25
ES2588279T3 (es) 2016-10-31
US20160230160A1 (en) 2016-08-11
US20170145402A1 (en) 2017-05-25
WO2011148041A1 (en) 2011-12-01
AU2011257092C1 (en) 2014-06-19
ZA201208948B (en) 2014-02-26
JP2013529905A (ja) 2013-07-25
CA2800671A1 (en) 2011-12-01
US10041056B2 (en) 2018-08-07
CN103038341A (zh) 2013-04-10

Similar Documents

Publication Publication Date Title
ZA201208948B (en) Modified beta-lactamases and methods and uses related thereto
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
IL221511A (en) Arilatriazolones associated with bis aryl and their use
IL226904A (en) Inganol-3-acetylates iii and Inganol-3-carbamates
ZA201208173B (en) Peptices and their use
IL220812A0 (en) Compounds and methods
PT2531518T (pt) Compostos oligopeptídicos e suas utilizações
EP2523560A4 (en) CONNECTIONS AND METHODS
ZA201303773B (en) Compounds and their use
PL2552440T3 (pl) Nowa kombinacja i zastosowanie
GB201018650D0 (en) Methods and compositions
GB201004450D0 (en) Compounds and methods relating thereto
GB201001384D0 (en) Light-fitting and associated methods
GB201000305D0 (en) Compounds and their use
GB201000308D0 (en) Compounds and their use
GB201000307D0 (en) Compounds and their use
GB201000309D0 (en) Compounds and their use
GB201005511D0 (en) Compounds and their use
GB201017822D0 (en) Compounds and their use
GB201018028D0 (en) Compounds and their use
GB201002337D0 (en) Compounds and their use
GB201020848D0 (en) Compounds and their use
GB201009767D0 (en) Compositions and methods